2071636-70-7
Chemical Structure
Sudemycin K
- CAS No.: 2071636-70-7
- Formula:C29H46N2O4
- Molecular Weight:486.69
IUPAC Name: (S,Z)-N-(4-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)cyclohexyl)-4-isobutyramidopent-2-enamide
InChIKey: UAXSPVBRWFTUJB-QVKVUSCISA-N
SMILES: C[C@H](NC(C(C)C)=O)/C=C\C(NC1CCC(C/C=C(C)/C=C/[C@@H](OC(C)(C)C2)C[C@@]32CO3)CC1)=O
Biological Activity: Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sudemycin K | Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
